Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07227506 · ClinicalTrials.gov registry record

Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:

A clinical trial of Eosinophilic Esophagitis and GERD, sponsored by Medical College of Wisconsin.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT07227506 is a study of Eosinophilic Esophagitis and GERD that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 50 participants, below the 863-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07227506, a study of Eosinophilic Esophagitis and GERD, is actively recruiting participants, sponsored by Medical College of Wisconsin.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making. Aim: Here, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.

Interventions

  • DEVICE MuVI Esophageal mucosal impedance testing

Study Locations (1)

Wisconsin

  • Froedtert Hospital - Milwaukee

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-11-20
Est. Completion 2028-07-01

Sponsor

Medical College of Wisconsin

447 total trials

What the Registry Record Tells You About NCT07227506

The ClinicalTrials.gov registry entry for NCT07227506 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 863-participant average among 44 other Eosinophilic Esophagitis trials with a reported enrollment target (94% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Eosinophilic Esophagitis appearing as the primary indexed condition, and to 1 intervention - of which MuVI Esophageal mucosal impedance testing is the first listed.

NCT07227506 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.

Frequently Asked Questions

What is clinical trial NCT07227506 about?

NCT07227506 is a clinical study titled "Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:". Background \& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GER...

What is the current status of trial NCT07227506?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-11-20. Estimated completion is 2028-07-01.

What conditions does trial NCT07227506 study?

This clinical trial studies the following conditions: Eosinophilic Esophagitis, GERD.

What interventions are being tested in trial NCT07227506?

The interventions under investigation include: MuVI Esophageal mucosal impedance testing (DEVICE).

Who is sponsoring clinical trial NCT07227506?

This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07227506 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Eosinophilic Esophagitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.